Jonas Kulhavy
Wuerzburg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 08, 2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Journal: JCO precision oncology
Published: August 06, 2025
Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.
Journal: ESMO open
Published: January 08, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 12, 2024
Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158].
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 30, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 12, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.
Journal: Clinical lung cancer
Published: March 26, 2024
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 12, 2024
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 24, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026